Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma

无容量 医学 易普利姆玛 中止 内科学 不利影响 间皮瘤 外科 胃肠病学 肿瘤科 免疫疗法 癌症 病理
作者
D. Dumoulin,Li-Anne H Douma,M.M. Hofman,Vincent van der Noort,Robin Cornelissen,Cornedine J. de Gooijer,Jacobus A. Burgers,Joachim Aerts
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:187: 107440-107440
标识
DOI:10.1016/j.lungcan.2023.107440
摘要

ObjectivesNivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is a new first-line treatment combination for patients with pleural mesothelioma. Nivolumab-ipilimumab improved the survival, however, 30.3% of the patients suffered from grade 3–4 treatment related adverse events (TRAE’s) and TRAE’s led to discontinuation in 23.0% of all patients. Here, we present the first real-world data of nivolumab plus ipilimumab in patients with malignant mesothelioma treated in two mesothelioma expert centers.MethodsClinical data of patients with mesothelioma treated with nivolumab and ipilimumab were prospectively collected. Clinical parameters were obtained every visit, CT scans were evaluated every 12 weeks and adverse events were assessed continuously during the treatment. Data on grade 2–5 TRAE’s and activity (overall response rate (ORR), duration of response (DOR), disease control rate (DCR), median progression-free survival (mPFS) and median overall survival (mOS) were reported.ResultsBetween January 2021 and August 2022, 184 patients were treated with nivolumab plus ipilimumab. The median follow-up was 12.1 months (95 %CI 11.1 – 13.1). Grade 3–4 TRAEs were seen in 27.7 % of the patients and 25.0 % discontinued immunotherapy treatment early because of TRAE’s. ORR was 21.7 % (95 % CI 15.7–27.7), median DOR was 5.7 months (IQR 3.2–8.7) and DCR at 12 weeks 56.0 % (95 % CI 48.8–63.2). The mPFS was 5.5 months (95 %CI 4.1–6.9), mOS was 14.1 months (95 % CI 11.1–18.2).ConclusionsNivolumab plus ipilimumab had an equal efficacy in a real-world comparable population but also a high risk of TRAE’s, leading to discontinuation of treatment in 25% of the patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yang完成签到,获得积分10
1秒前
123123完成签到 ,获得积分10
2秒前
温暖宛筠完成签到,获得积分10
2秒前
小欣6116完成签到,获得积分10
3秒前
请叫我风吹麦浪应助冬月采纳,获得10
3秒前
LIUYONG发布了新的文献求助10
4秒前
4秒前
肖雪依完成签到,获得积分10
4秒前
影子完成签到,获得积分10
5秒前
6秒前
晨珂完成签到,获得积分10
6秒前
Florencia发布了新的文献求助10
8秒前
xiezhuochun发布了新的文献求助10
9秒前
9秒前
同瓜不同命完成签到,获得积分10
11秒前
牛马哥发布了新的文献求助10
12秒前
温婉的松鼠完成签到,获得积分10
12秒前
13秒前
辛勤的寄瑶完成签到,获得积分10
13秒前
Lauren完成签到 ,获得积分10
14秒前
15秒前
忆枫完成签到,获得积分10
19秒前
炒鸡小将发布了新的文献求助10
19秒前
花壳在逃野猪完成签到 ,获得积分10
19秒前
19秒前
银子吃好的完成签到,获得积分10
20秒前
西瓜霜完成签到 ,获得积分10
20秒前
科研废物完成签到 ,获得积分10
22秒前
冬月完成签到,获得积分10
22秒前
22秒前
马东完成签到,获得积分10
24秒前
搜集达人应助动听的秋白采纳,获得10
24秒前
25秒前
量子星尘发布了新的文献求助10
25秒前
华仔应助炒鸡小将采纳,获得10
26秒前
chizhi完成签到,获得积分10
26秒前
雪雨夜心应助白智妍采纳,获得10
27秒前
祁乐安发布了新的文献求助20
28秒前
fang应助科研通管家采纳,获得10
29秒前
梵高的向日葵完成签到,获得积分10
29秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029